Proud Partners of AVMI

Techinvention is Strategic advisory and Technology providing firm which is focused exclusively on the capacity building of Vaccines and Biologicals for the developing world.

Techinvention has enabled quite a few successful outcomes of capacity building projects from Concept stage to Commercial Manufacture. The Projects have encompassed all 3 models of : a) Forward Integration b) Backward Integration and c) Hybrid Concept.

We are currently working on a platform technology that will render a vaccine for COVID-19 effective and affordable along with an engineering solution that can enable set up of a manufacturing facility that’s compliant and affordable.

Using this concept, other essential recombinant vaccines can also be manufactured in the same facility on a campaign basis. This approach enables capacity building for pandemic preparedness as well as indigenous manufacture of specific vaccines in the EPI for the developing world and particularly Africa.

Visit their website here

We are Merck, a vibrant science and technology company. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create.

Healthcare, Life Science and Performance Materials are our core businesses. In all three sectors, we offer specialized and high-quality products.

For more than 350 years, we have been pushing the boundaries of possibility. Thanks to the constant curiosity of more than 7,200 R&D professionals, we are discovering and developing technologies that can change the landscape of entire industries. We partner with those who share our passion. Our clear goal is to achieve progress for patients, customers and society as a whole. This is what we work for every day.

Our purpose is to solve the toughest problems in life science by collaborating with the global scientific community – and through that, we aim to accelerate access to better health for people everywhere.

From small start-up laboratories, to the largest manufacturers, we provide scientists and engineers with best-in-class lab materials, technologies and services. With the 2015 combination of Millipore and Sigma-Aldrich, we now have a broad portfolio of 300,000 products, an expanded global footprint and an industry-leading eCommerce platform.

Vaccine manufacturing can have tremendous challenges. From early phase development, to large scale production, our process development engineers, regulatory experts and comprehensive portfolio of products and services can help manufacturers meet their process goals.

Visit their website here

Visit their website here

IAVI is a nonprofit scientific research organization that develops vaccines and antibodies for HIVtuberculosisemerging infectious diseases (including COVID-19), and neglected diseases. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Through scientific and clinical research in Africa, India, Europe, and the U.S., IAVI is pioneering the development of biomedical innovations designed for broad global access.


In Africa, IAVI focuses on research and development (R&D), research preparedness, and policy and advocacy work. Our work includes strengthening the capacity for cutting-edge basic, clinical, epidemiological, and translational research across multiple disease areas in sub-Saharan Africa (SSA) through a robust research and capacity development program. In collaboration with clinical research center (CRC) partners across Eastern, Western, and Southern Africa, IAVI is contributing to the development of next-generation vaccines for HIV and tuberculosis (TB); biomedical interventions for the prevention and control of emerging infectious diseases and other neglected tropical diseases; and antibody discovery and development for HIV prevention, treatment of snakebite, and multi-drug resistant bacteria.


By facilitating meaningful engagement with communities, advocates, and policymakers, IAVI supports the development of national and regional policies that enhance the research and regulatory environment and accelerate translation of research to policy and practice.



Visit their website here

The Advancing Vaccine Production for Africa (AVPA) initiative focuses on identifying the key challenges and opportunities for vaccine production and innovation in Africa. It has two specific goals: to identify technology gaps in the vaccine sector in Africa, both in public research and private sector companies, and to build the vaccine innovation ecosystem in Africa by strengthening its public sector institutions.

The initiative fosters a centres of excellence network to support the emergence of manufacturing capacity in the region built on robust university-industry collaborations, and a strong African public sector that focuses on translational research for vaccines.

Visit their website here: